Michael Daniel

Promote Perseris, the first once-monthly subcutaneous risperidone containing, long-acting injectable for the treatment of schizophrenia in adults.

Target panel includes Psychiatrists, NP’s and PA’s, that treat adults with schizophrenia in out-patient and crisis unit settings.

Finished Q2 2019 292% to TRX goal and 200% to HCP goal.

Finished mission P4 launch contest number 4 in nation, 245% combined goal.

Clinical Specialist of Q2 2019.

Finished 2019 181% TRX goal and #4 in the nation

Winner of see it, own it, make it happen award 2019~23

First and only rep to reach 600+ Perseris RX's

Finished 2020 #2 in nation.

Finished 2021 #5 in nation.

Finished 2022 #1 in nation.

Finished 2023 #4 in nation.

5 time Behavior Health Elite Award winner.

Promote first and only ODT XR ADHD medication to Pediatricians, Adult/Pediatric Psychiatrist, and Family Practice physicians.

Started in a territory ranked 127th out of 129th

Finished Q3 ranked 30 out of 129

Finished Q3 with a growth rank of #3 in country.

Q3 growth average of 275% with both Adzenys XR ODT and Cotempla XR ODT. .

Sales Representative of Year 2000, 2001. Specialty Sales Representative of Year 2002, 2005, 20012.
Presidents Club 2001, 2002, 2005, 2012.
Specialty field sales trainer 2002-2013.
Specialty Representative of Q1-2012, Q1-2013, Q4-2013.
Multiple Bear Award Winner.
Lead multiple drug launches, across multiple drug classes, which include, Celexa, Lexapro, Benicar, Benicar HCT, Campral, Bystolic, Savella, Fetzima, Namenda , Namenda XR, Namzaric, Viibryd, Linzess, Saphris and Vraylar.
Experienced in multiple specialty markets including Psychiatry, Gastroenterology, Neurology, Cardiology, Pulmonology, OBGYN, Endocrinology, Pain Management and Rheumatology.
Multiple Top 10% finishes since employment.
Finished 20 out of 515 with Viibryd in 2016.
Increased Namzaric from 85% of goal, to 108% of goal 2016.
Increased Namzaric ranking from 78% to top 12% in 2016.
Finished 11 out of 493 with Namzaric new prescibers Q1 2017.
Finished 8 out of 517 with Viibryd in 2016.
Finished 20 out of 517 with Vraylar 2017.
Finished 17 out of 493 with Linzess 2017.
Had highest growing Vraylar adopters in Q2, Q3 2017.
Lead, coach and develop 8-10 territory representatives to achieve a common goal of market share growth.
Analyzed territory data to maximize areas of opportunity and market trends.
Demonstrated effective use of product and technical knowledge.
Provide information and competitive advantages of five in-line products to over 300 physicians.
Plan and develop speaker programs in territory to maximize impact of product and disease state.
Coordinate with Manager of Specialty Markets to ensure formulary coverage and best positioning of products.

Played professional baseball for the Montreal Expos, Minnesota Twins, Florida Marlins and Pittsburgh Pirates.
Negotiated yearly contracts as well as educational incentives.
Provide professional baseball instruction to kids of all ages.